MedTrace Logo

A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy

NCT00225095 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-12-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether Chondrogen is a safe and effective post-operative treatment of the knee following menisectomy (the surgical removal of all or part of a torn meniscus).

Conditions

  • Recovery Following Partial Medial Meniscectomy

Interventions

DRUG

Mesenchymal Stem Cells

DRUG

Hyaluronan

Sponsors & Collaborators

  • University of Southern California

    collaborator OTHER

  • Midwest Orthopedics at Rush - Chicago, IL

    collaborator UNKNOWN

  • Unlimited Research - San Antonio, TX

    collaborator UNKNOWN

  • Triangle Orthopaedic Associates, P.A.

    collaborator OTHER

  • Orthopedic Center of Vero Beach - Vero Beach, FL

    collaborator UNKNOWN

  • OrthoIndy

    collaborator OTHER

  • TRIA Orthopaedic Center

    collaborator OTHER

  • Greater Chesapeake Orthopaedic Associates, LLC

    collaborator OTHER

  • Mesoblast International Sàrl

    lead INDUSTRY

Principal Investigators

  • Michelle Williams, Ph.D. · Osiris Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00225095 on ClinicalTrials.gov